

## **Product datasheet for TL309789**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## RNF139 Human shRNA Plasmid Kit (Locus ID 11236)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** RNF139 Human shRNA Plasmid Kit (Locus ID 11236)

**Locus ID:** 11236

Synonyms: HRCA1; RCA1; TRC8

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** RNF139 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 11236).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 007218, NM 007218.1, NM 007218.2, NM 007218.3, BC064636, BC021571, BM677460,

BM804626, NM 007218.4

UniProt ID: O8WU17

**Summary:** The protein encoded by this gene is a multi-membrane spanning protein containing a RING-

H2 finger. This protein is located in the endoplasmic reticulum, and has been shown to possess ubiquitin ligase activity. This gene was found to be interrupted by a t(3:8)

translocation in a family with hereditary renal and non-medulary thyroid cancer. Studies of the Drosophila counterpart suggested that this protein may interact with tumor suppressor protein VHL, as well as with COPS5/JAB1, a protein responsible for the degradation of tumor

suppressor CDKN1B/P27KIP. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).